Q-omics provides the consensus-scored MIAT profile across patient tissues and cancer cell-line models. MIAT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MIAT is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MIAT RNA expression shows 17,531 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where MIAT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIAT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIAT survival associations across molecular data types. MIAT RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIAT RNA expression–survival associations across cancer types. High MIAT expression shows unfavorable associations in KIRC, UVM and KIRP, but favorable associations in SKCM, HNSC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MIAT RNA expression.
This table summarizes MIAT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIAT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIAT shows higher tumor expression in KIRC, HNSC, BRCA, STAD, LUSC and THCA. The KIRC box plot shows higher MIAT RNA expression in tumor versus normal tissue (log2 FC = +0.617, t-test p < 0.001).
This table shows molecular features associated with MIAT in patient tissues and cancer cell lines. In patient samples, MIAT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
